Novo Nordisk has endured a prolonged period of setbacks, including sharply increased competition in the weight-loss drug segment from rival Eli Lilly.
However, in its first quarterly report of the year, the company surprised the market.
The company reported a lower adjusted operating profit for the first quarter than in the previous year. However, the profit was above analysts' expectations. Adjusted sales of DKK 70 billion followed the same pattern, that is, worse than the previous year but still better than expected.
Novo Nordisk is also raising its forecast for 2026 as the weight-loss drug Wegovy is selling better than expected, helped by a pill version launched in January.
Correction: A previous version contained an incorrect description of the price increase.
